SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pfizer - Quaterly Results

11 Nov 2022 Evaluate
The quarter ended September 2022 witnessed marginal change in the total revenue. The figure for the mentioned quarter is pegged at Rs. 6374.70 millions.The Net Profit of the company reported a remarkable increase of 117.61% to Rs. 3110.70  millions  from Rs. 1429.50 millions in previous same quarter.Operating profit surged to 2559.30 millions from the corresponding previous quarter of 2044.00 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 6374.70 6362.60 0.19 12303.70 13854.30 -11.19 26109.90 22385.50 16.64
Other Income 242.40 150.30 61.28 422.60 272.70 54.97 626.50 811.20 -22.77
PBIDT 2559.30 2044.00 25.21 4658.00 5023.80 -7.28 8983.80 7932.40 13.25
Interest 33.80 22.10 52.94 70.20 44.60 57.40 104.90 151.10 -30.58
PBDT 4414.70 2021.90 118.34 5113.70 4979.20 2.70 8878.90 7781.30 14.11
Depreciation 262.50 272.30 -3.60 527.60 542.30 -2.71 1150.00 1094.10 5.11
PBT 4152.20 1749.60 137.32 4586.10 4436.90 3.36 7728.90 6687.20 15.58
TAX 1041.50 320.10 225.37 1149.90 1008.30 14.04 1603.30 1711.10 -6.30
Deferred Tax -31.90 -97.50 -67.28 -186.00 -117.20 58.70 -359.30 -125.20 186.98
PAT 3110.70 1429.50 117.61 3436.20 3428.60 0.22 6125.60 4976.10 23.10
Equity 457.50 457.50 0.00 457.50 457.50 0.00 457.50 457.50 0.00
PBIDTM(%) 40.15 32.13 24.97 37.86 36.26 4.40 34.41 35.44 -2.90

Pfizer Share Price

4865.30 116.75 (2.46%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×